LYSOSOMAL AND RARE DISORDERS RESEA… - Form 990 Financial Data

🔒

Financial Vulnerability Assessment (Tuckman-Chang)

4 risk indicators measuring financial stability and operational resilience

Sign in with your work email to view Tuckman-Chang indicators

Financial Trends

Organization Details

Formation Year

2012

Legal Domicile

Principal Officer

DR OZLEM GOKER-ALPAN

Phone

7032616220

Tax Period

2023-01-01 to 2023-12-31

LYSOSOMAL AND RARE DISORDERS RESEARCH AND TREATMENT CENTER INC, founded in 2012, is a community nonprofit in the Medical Research sector that reported $3.4M in total revenue in fiscal year 2023. Revenue grew 11% year-over-year, indicating healthy expansion.

Mission

LYSOSOMAL AND RARE DISORDERS RESEARCH AND TREATMENT CENTER INC'S (LDRTC) MISSION IS TO PROVIDE RESEARCH TO UNRAVEL UNDERLYING DISEASE-CAUSING MECHANISMS, DISCOVER NEW BIOMARKERS AND EXPLORE NEW THERAPEUTIC PATHWAYS AND TREATMENT OPTIONS. FURTHER, LDRTC WORKS TO EDUCATE PATIENTS, FAMILIES, HEALTHCARE PROVIDERS AND RESEARCHERS IN THE FIELD. FINALLY, IT PROVIDES TREATMENT AND CLINICAL CARE TO PERSONS SUFFERING FROM LYSOSOMAL AND OTHER RARE DISEASES.

Program Service Accomplishments

Program 1

Expenses: $2,072,878 Revenue: $2,634,495

TREATMENT & CLINICAL CARE: IN LDRTC'S CLINIC, LDRTC OFFERS EXTENSIVE MEDICAL GENETIC EVALUATIONS FOR COMPLEX MEDICAL PROBLEMS OF UNKNOWN ETIOLOGY AND THAT DO NOT FIT A PARTICULAR DISEASE PATTERN...

TREATMENT & CLINICAL CARE: IN LDRTC'S CLINIC, LDRTC OFFERS EXTENSIVE MEDICAL GENETIC EVALUATIONS FOR COMPLEX MEDICAL PROBLEMS OF UNKNOWN ETIOLOGY AND THAT DO NOT FIT A PARTICULAR DISEASE PATTERN. CASE STUDIES INVOLVING INDIVIDUALIZED THERAPY, INSTITUTIONAL COLLABORATIONS AND INDIVIDUAL BENCH SCIENCE PROJECTS WERE SUCCESSFUL DURING THE PAST YEAR.

Program 2

Expenses: $947,665 Revenue: $197,815

RESEARCH: LDRTC AIMS TO BRIDGE THE GAP BETWEEN BASIC AND CLINICAL RESEARCH TO FACILITATE THE DIAGNOSIS, TREATMENT, AND MANAGEMENT OF RARE DISORDERS. LDRTC PRESENTS A UNIQUE TRANSLATIONAL RESEARCH...

RESEARCH: LDRTC AIMS TO BRIDGE THE GAP BETWEEN BASIC AND CLINICAL RESEARCH TO FACILITATE THE DIAGNOSIS, TREATMENT, AND MANAGEMENT OF RARE DISORDERS. LDRTC PRESENTS A UNIQUE TRANSLATIONAL RESEARCH MODEL FOCUSING ON A MULTIDISCIPLINARY APPROACH TO STUDY THE DISEASE PATHOLOGY, WHILE APPLYING CELLULAR, MOLECULAR, AND IMMUNOLOGIC CONCEPTS TO PATHWAYS AMENABLE TO THERAPEUTIC MODULATION.

Program 3

Expenses: $312,297 Revenue: $27,980

EDUCATION: EDUCATION IS FOCUSED AROUND PATIENT MEETINGS, WORKSHOPS, LECTURE SERIES, CONFERENCES, SYMPOSIUMS AND INTERNSHIPS. LDRTC HOLDS VARIOUS WORKSHOPS DESIGNED TO PROVIDE OPPORTUNITIES FOR ITS...

EDUCATION: EDUCATION IS FOCUSED AROUND PATIENT MEETINGS, WORKSHOPS, LECTURE SERIES, CONFERENCES, SYMPOSIUMS AND INTERNSHIPS. LDRTC HOLDS VARIOUS WORKSHOPS DESIGNED TO PROVIDE OPPORTUNITIES FOR ITS ATTENDEES TO COLLABORATE AND PROMOTE DISCUSSIONS ON ALL ASPECTS OF LYSOSOMAL BIOLOGY.

🔒

Trantor Score

Financial Health Score (300–850) · Liquidity · Solvency · Sustainability · Efficiency

Sign in to view Trantor Score and financial metrics

Liquidity (40%) • Solvency (30%) • Sustainability (20%) • Efficiency (10%)

Financial Overview (2023)

Revenue Breakdown

Contributions & Grants $491,100

Program Service Revenue $2,860,290

Investment Income $0

Other Revenue $0

TOTAL REVENUE $3,351,390

Expense Breakdown

Grants Paid $5,000

Salaries & Benefits $1,694,420

Fundraising Expenses $0

Program Expenses $3,332,840

Other Expenses $1,977,294

TOTAL EXPENSES $3,676,714

Year-over-Year Comparison

	2023	2022	Change
Revenue	$3,351,390	$3,020,151	+0.1%
Expenses	$3,676,714	$2,474,219	+0.5%
Net Income	$-325,324	$545,932	-1.6%

Key Indicators

✗ Grants to Organizations ✗ Grants to Individuals ✗ Lobbying ✗ Political Activity ✗ Foreign Activities ✗ Donor Advised Fund ✓ Schedule B Required

🔒

Financial Health Indicators

Comprehensive financial analysis: Altman Z-Score, liquidity, solvency, sustainability, efficiency, and growth metrics

Financial Distress Indicator

Liquidity & Cash Position

Sign in to view all financial metrics

Altman Z-Score • Liquidity Ratios • Solvency Analysis • Growth Indicators • Efficiency Metrics

Governance

Voting Members

Independent Members

N/A

Employees

Volunteers

Governance Policies

✓ Conflict of Interest Policy

✓ Whistleblower Policy

✓ Document Retention Policy

Special Practices & Reported Activities

✗ Operated a School

✗ Operated a Hospital

✗ Provided First Class Travel

✗ Reported Conflict of Interest

✗ Reported Asset Diversion

✗ Excess Benefit Transaction

✗ Made Political Expenditures

✗ Engaged in Lobbying

✗ Operated Donor Advised Fund

✗ Maintained Art Collections

✗ Filed Form 720

Compensation of Officers, Directors & Key Employees

Total Officers

$446,512

Total Directors

$551,941

Key Employees

Highest Compensated

reported

Name	Title	Hours/Week	Role	Reportable Comp	Other Comp	Total
DR OZLEM GOKER-ALPAN	PRESIDENT / FOUNDER	16.00	Officer Director	$289,151	$7,804	$296,955
LAUREN NOLL	DIRECTOR / MANAGER	8.00	Director	$101,862	$3,567	$105,429
BOBBY SANDHU	SECRETARY / LPN	8.00	Officer Director	$73,800	$0	$73,800
UYENSA BEESE	TREASURER / OPERATIONS DIRECTOR	24.00	Officer Director	$70,458	$5,299	$75,757
MARGARITA IVANOVA	DIR. OF TRANSLATIONAL RESEARCH	40.00	Highest	$112,241	$0	$112,241
LIA H VAN	NURSE PRACTITIONER	40.00	Highest	$105,715	$0	$105,715

Note: Compensation data is self-reported by the organization on their Form 990. "Reportable Comp" includes salary, bonuses, and other reportable compensation from the organization and related organizations. "Other Comp" includes benefits, deferred compensation, and non-taxable benefits.

Historical Data

Year	Revenue	Expenses	Assets	Net Income
2024	No data	No data	No data	No data
2023	$3,351,390	$3,676,714	$1,851,613	$-325,324
2022	$3,020,151	$2,474,219	$2,144,032	$545,932
2021	$2,664,551	$2,093,309	$1,635,612	$571,242
2020	$1,934,480	$2,201,912	$834,123	$-267,432

LYSOSOMAL AND RARE DISORDERS RESEARCH AND TREATMENT CENTER INC